Tamar Securities LLC Acquires 4,393 Shares of Elevance Health, Inc. $ELV

Tamar Securities LLC boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 5.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 87,406 shares of the company’s stock after acquiring an additional 4,393 shares during the quarter. Elevance Health accounts for 3.2% of Tamar Securities LLC’s portfolio, making the stock its 9th largest position. Tamar Securities LLC’s holdings in Elevance Health were worth $30,640,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in ELV. Norges Bank acquired a new stake in Elevance Health in the 4th quarter valued at approximately $1,058,165,000. Bank of New York Mellon Corp increased its position in shares of Elevance Health by 79.3% during the 4th quarter. Bank of New York Mellon Corp now owns 2,408,704 shares of the company’s stock valued at $844,371,000 after purchasing an additional 1,065,065 shares during the period. Artisan Partners Limited Partnership increased its position in shares of Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC increased its position in shares of Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after purchasing an additional 798,457 shares during the period. Finally, Brave Warrior Advisors LLC increased its position in shares of Elevance Health by 65.3% during the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock valued at $592,603,000 after purchasing an additional 724,349 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ELV shares. Truist Financial lifted their price target on Elevance Health from $375.00 to $450.00 and gave the company a “buy” rating in a research report on Monday, June 1st. Barclays lifted their price target on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research report on Tuesday, May 26th. Leerink Partners set a $364.00 price target on Elevance Health in a research report on Thursday, April 23rd. UBS Group lifted their price target on Elevance Health from $400.00 to $460.00 and gave the company a “buy” rating in a research report on Friday, May 22nd. Finally, Citigroup upgraded Elevance Health to a “buy” rating in a research report on Wednesday, April 29th. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $416.11.

Elevance Health Stock Performance

ELV opened at $403.74 on Monday. The firm has a market cap of $87.68 billion, a PE ratio of 17.17, a P/E/G ratio of 2.29 and a beta of 0.67. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The business has a fifty day simple moving average of $366.62 and a 200-day simple moving average of $344.97. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $426.98.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s revenue was up 1.5% compared to the same quarter last year. During the same period last year, the company posted $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 26.93 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 annualized dividend and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is currently 29.26%.

Insider Buying and Selling at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the sale, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.34% of the stock is currently owned by corporate insiders.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.